Bookmark and Share

Olga G Goloubeva
 

Olga G Goloubeva Ph.D., M.Sc.

Academic Title: Associate Professor
Primary Appointment: Epidemiology & Public Health
ogoloubeva@som.umaryland.edu
Location: Howard Hall, 111
Phone: (410) 706-8502
Phone: (410) 706-8505
Fax: (410) 706-8548

Personal History:

M.Sc., Fellowship and Assistantship, Dalhousie University, Halifax, Nova Scotia, Canada (Mathematical Statistics Thesis: "Left-censoring in medical trials: A likelihood approach")

PhD, Engineering: Optimization of industrial processes, State Technical University, Moscow, Russia (
PhD confirmed and approved by University of Toronto, Toronto, Canada/Comparative Education Service of Canada)
       
M.Sc., B.S. Engineering: Development of advanced materials and technologies, National University of Science and Technology, Moscow, Russia


Research Interests:

Statistical design and analysis of laboratory, clinical and epidemiological studies in all types of cancer as well as other diseases.

Statistical expertise lies in the design and analysis of preclinical studies and clinical trials, evaluation of diagnostic tests, biomarkers and their combination, prognostic models of cancer, longitudinal and hierarchical data modeling.


Publications:

Peer-reviewed journal articles since 2000

Leneva, I.A., Roberts, N., Govorkova, E.A., Goloubeva, O.G., Webster, R.G. The neuraminidase inhibitor GS4 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Research, 48, 101-115. 2000 (Data analysis, manuscript writing).

Glass, J.O.,Reddick, W.E., Goloubeva, O.G., Yo, V., Steen, G.R. Hybrid artificial neural network segmentation of precise and accurate inversion recovery (PAIR) images from normal human brain. Magnetic Resonance Imaging, 18, 1245-1253, 2000. (Data analysis, manuscript writing).

Palmer, S.L., Goloubeva, O.G., Glass, J.O.,Reddick, W.E., Gajjar, A., Kun, T.E., Merchant, T.E., Mulhern, R.K. Patterns of Intellectual Development Among Survivors of pediatric Medulloblastoma: A Longitudinal Analysis. Journal of Clinical Oncology, 19, 2302-2308, 2000. (Data analysis, manuscript writing).

Seo, S.H., Goloubeva, O.G., Webby, R., and Webster, R.G. Characterization of a Porcine Lung Epithelial Cell Line Suitable for Influenza Virus Studies. Journal of Virology, 75: 9517-9525, 2001 (Data analysis, manuscript writing).

Govorkova, E.A., Leneva, I.A., Goloubeva, O.G., Bush, K., Webster, R.G. Comparison of the efficacy of RWJ-270201, zanamivir, and oseltamivir against (H5N1) and (H9N2), and other avian influenza viruses. Antimicrobial Agents and Chemotherapy, 45: 2723-2732, 2001. (Design, data analysis, manuscript writing).

McCarville, M.B., Kaste, S.C., Cain, A.M., Goloubeva, O.G., Rao, B.N., Pratt, C.B. Prognostic Factors and Imaging Patterns of Recurrent Pulmonary Metastasis after Thoracotomy in Children with Osteosarcoma. Cancer, 91: 1170-1176, 2001. (Data analysis, manuscript writing).

Smeyne, M., Goloubeva, O.G., Smeyne, R.J. Strain-Dependent Susceptibility to MPTP and MPP+ - Induced Parkinsonism Is Determined by Glia. GLIA, 34, 73-80, 2001. (Data analysis, manuscript writing).

Leneva, I.A., Goloubeva, O.G., Fenton, R.J., Tisdale, M., and Webster, R.G. Efficacy Of Zanamivir against Avian Influenza A Viruses That Possess Genes Encoding H5N1 Internal Proteins and Are Pathogenic in Mammals. Antimicrobial Agents and Chemotherapy, 45, 1216-1224, 2001. (Data analysis, manuscript writing).

McCarville, M.B., Hoffer, F.A., Howard, S.C., Goloubeva, O.G., Kaufman, W.M. Hepatic veno-occlusive disease in children undergoing bone-marrow transplantation: usefulness of sonographic findings. Pediatric Radiology, 31, 102-105, 2001. (Data analysis, manuscript writing).

Palmer, S.L., Reddick, W.E., Glass, J.O., Gajjar, A., Goloubeva, O.G., Mulhern, R.K. Decline in corpus callosum volume among pediatric patients with Medulloblastoma. Longitudinal MR Imaging Study. American Journal of Neuro-Radiology, 23(7): 1088-1094, 2002. (Data analysis, manuscript writing).

Merchant, T.E., Goloubeva, O.G., Pritchard, D.L., Gaber, M.W., Xiong, X., Danish, R.K., Lusting, R.H. Radiation Dose-Volume Effects on Growth Hormone Secretion. Int J Radiat Oncol Biol Phys., 52(5), 1264-70, 2002. (Data analysis, manuscript writing).

Cunningham, J.J., Levine, E.M, Zindy, F., Goloubeva, O.G., Roussel, M.F., and Smeyne, R.J. The Cycline-Dependent Kinase Inhibitors, p19Ink4d and p27Kip1 are co expressed in select retinal cells and act cooperatively to control cell cycle exit. Mol. Cell Neurosci, 19, 359-374, 2002. (Data analysis, manuscript writing).

Langley J.M., LeBlanc J.C., Hanakowski M, Goloubeva O. The role of Clostrida difficile and viruses as causes of nosocomial diarrhea in children. Infection Control and Hospital Epidemiology, 23: 660-664, 2002. (Data analysis, manuscript writing).

LeBlanc R., Catley L., Hideshima T., Lentzsch S., Mitsiades C., Mitsiades N., Neuberg D., Goloubeva O., Pien C., Adams J., Gupta D., Richardson P., Munshi N., Anderson K. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Research, 62(17): 4996-5000, 2002. (Data analysis, manuscript writing)

Haight, A., Kaste, S.C., Goloubeva, O.G., Xiong, X., Bowman, L.B. Nephrotoxicity of Iopamidol in Pediatric, Adolescent, and Young Adult Patients Who Have Undergone Allogeneic Bone Marrow Transplantation. Radiology, 226:399-404, 2003. (Data analysis, manuscript writing).

Hou R., Goloubeva O.G., Neuberg D.S., Strominger J.L., Wilson S.B. Interleukine-12 and interleukine-2-induced invariant natural killer T-cell cytokine secretion and perforin expression independent of T-cell receptor activation. Immunology, 110(1): 30-37, 2003. (Data analysis, manuscript writing)

Paietta E., Goloubeva O., Bennett J., Gallagher R., Racevskis P., Tallman M. A surrogate marker profile for PML/RAR expressing APL and the association of immunophenotypic markers with morphologic and molecular subtypes. Clinical Cytometry, 59B: 1-9, 2004. (Data analysis, manuscript writing).

Long BJ, Jelovac D, Handratta V, MacPherson N, Ragaz J, Goloubeva OG, Brodie AM. Therapeutic Strategies Using the Aromatase Inhibitor Letrozole and Tamoxifen in a Breast Cancer Model. J Natl Cancer Inst., 96: 456-465, 2004. (Data analysis, manuscript writing).

Huang L, Kim P, Nickoloff J, Goloubeva OG, Morgan WF. Ionizing Radiation Induces Delayed Hyperrecombination in Mammalian Cells. Molecular and Cellular Biology, 24 (11): 5060-5068, 2004. (Data analysis, manuscript writing).

Jelovac D, Macedo L., Long BJ, Handratta V, Goloubeva OG, Ingle JN, Brodie AM Effects of Exemestane and Tamoxifen in a Postmenopausal Breast Cancer Model. Clin Cancer Res., 10(21): 7375-81, 2004. (Data analysis, manuscript writing).

Wiernic PH, Paietta E, Makower D, Goloubeva OG. Phase II study of theophylline in chronic lymphocytic leukemia. A study of Eastern Cooperative Oncology Group (E4998). Leukemia, Oct., 18(10): 1605-10, 2004. (Study design, data analysis, manuscript writing).

Patel JB, Huynh CK, Handratta VC, Brodie AM, Goloubeva OG, Soprano D, Njar VC. Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer in vitro and nude mice, J Med Chem, Dec 30; 47(37): 6716-29, 2004. (Data analysis, manuscript writing).

Ross DD., Shpritz D., Hull MM, Goloubeva O. Long-term evaluation of required coursework in palliative and end-of-life care for medical student. J Palliat Med., Oct. 8(5): 962-74, 2005 (Design data analysis, manuscript writing).

Dutcher L., Gallagher R., Hines L., Paiettta E., Goloubeva OG., Tallman M. Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia. A study of the Eastern Cooperative Oncology Group (E1993), Leuk Lymphoma, Mar 46(3): 377-85, 2005. (Data analysis, manuscript writing).

Jelovac D, Sabnis G, Long BJ, Macedo L, Goloubeva OG, Brodie AM. Aktivation of MAPK in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res., Jun 15: 65(12): 5380-9, 2005. (Data analysis, manuscript writing)

AZ Badros, OG Goloubeva, A Rappoport, B Ratterree, B Meisenberg, N Takebe, M Hayman, B Zhang, RG Fenton. Phase II study of G3139, Bcl-2 Antisense in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. JCO, Jun 20; 23(18): 4089-99, 2005. (Design, data analysis, manuscript writing).

Brodie A., Jelovac D., Macedo L., Sabnis G., Tilghman S., Goloubeva O. Therapeutic observations in MCF-7 aromatase xenografts. Clin Cancer Res., Jan 15: 11 (2 Pt 2): 884s-8s, 2005. (Data analysis, manuscript writing).

Takebe N, Cheng X, Wu S, Bauer K, Goloubeva OG, Fenton RG, Rappoport AP, Badros A, Ross D, Tricot G. Phase I clinical trial of inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients. Clin Cancer Res, Dec 15; 10(24): 8301-8, 2005. (Data analysis, manuscript writing).

Brodie A, Jelovac D, Sabnis G, Long B, Macedo L, Goloubeva OG. Model systems: mechanisms involved in the loss of sensitivity to letrozole. J Steroid Biochem Mol Biol. May; 95(1-5): 41-8, 2005. (Data analysis, manuscript writing).

Zhang Y, Wang XW, Jelovac D, Nakanishi T, Yu MH, Akinmade D, Goloubeva O, Ross DD, Brodie AM, Hamburger AW. The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells. Proc Natl Acad Sci USA.  102(28): 9890-5, 2005. (Data analysis, manuscript writing).

Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AM.  Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res., Jun 15; 65(12): 5439-44, 2005. (Data analysis, manuscript writing).

Sandra Brooks, Nancy Gordon, Chuanta Guo, Gloria Moses, Niharika Khann, Olga G Goloubeva, Shiraz Mishra.  Utilization of telephone lay counselors to improve health communication in an urban colposcopy clinic: a feasibility study. Journal of the association for academic minority physicians.  December: 40-45, 2005. (Data analysis, manuscript writing).

 Margolin DH, Saunders EH, Bronfin B, de Rosa N, Axthelm MK, Goloubeva O, Gelman RS, Letvin NL. Germinal center function in the spleen during simian HIV infection in rhesus monkeys. J Immunol. Jul15; 177(2): 1108-19, 2006. (Data analysis, manuscript writing).

Brett G. Masayesva, Elizabeth Mambo, Rodney J. Taylor, Olga G. Goloubeva, Shaoyu Zhou, Yoram Cohen, Khalid Minhas, Wayne Koch, James Sciubba, Anthony J. Alberg, Joseph Califano.  Mitochondrial DNA content increase in response to cigarette smoking. Cancer Epidemiol Biomarkers Prev., Jan: 15(1): 19-24, 2006. (Data analysis, manuscript writing).

Tang Y, Khan MA, Goloubeva O, Lee DI, Jelovac D, Brodie AM, Hussain A. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clin Cancer Res 12(1) January 1: 169-174, 2006.
(Design, data analysis, manuscript writing).

Ashraf Badros, Dianna Wiekel, Andrew Salama, Olga Goloubeva,  Abraham Schneider,Aaron Rappoport, Robert Fenton, Edward Sausville, Robert   Ord, and Timothy Meiller. Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk Factors. JCO, 24(6): February 20: 945-952, 2006. (Data analysis, manuscript writing).

Walser TC, Rifat S, Ma X, Kundu N, Ward C, Goloubeva O, Johnson MG, Medina JC, Collins TL, Fulton AM. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res. Aug 1; 66(15): 7701-7, 2006. (Data analysis, manuscript writing).

Andersen JB, Aaboe M, Borden EC, Goloubeva OG, Hassel BA, Orntoft FF. Stage-associated overexpression of the ubiquitin-like protei, ISG 15, in bladder cancer. Br J Cancer. May 22; 94(10): 1465-71, 2006. (Data analysis, manuscript writing).  

Badros A, Goloubeva O.G., Fenton R, Rapoport AP, Akpek G, Harris C, Ruehle K, Westphal S, Meisenberg B. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma. Clinical Lymphoma & Myeloma 7 (3): 210-216, 2006. (Design, data analysis, manuscript writing).

Badros A, Goloubeva O.G., Milliron T, Mize B, Streeten E. Prevalence and impact of Vitamin D Deficiency in Multiple Myeloma Patients. Br J Haematol. Jul; 142(3): 492-4, 2008. (Data analysis, manuscript writing).

Tkaczuk K, Goloubeva O, Lum Z-P, Tait NS, Lesko SA, Feldman F, Tan M, Van Echo DA, Ts'o P. The Significance of Circulating Epithelial Cells in Patients with Breast Cancer. Breast cancer Res Treat Sept 111(2): 355-64, 2008. (Data analysis, manuscript writing).

Sabnis G, Macedo L, Goloubeva O, Schayowitz A, Zhu Yeu, Brodie A. Toremifene-Atamestane; Alone or in Combination: Predictions from the Preclinical Intratumoral Aromatase Model. J Steroid Biochem Mol Biol Jan 108(1-2): 1-7, 2008. (Data analysis, manuscript writing).

Sabnis G, Goloubeva O, Jelovac D, Schayowitz A, Brodie A.  Inhibition of the phosphatidylinositol 3-kinase K/Akt pathway impoves response of long term estrogen deprived breast cancer xenografts to antiestrogens. Clin Cancer Res, May 1st, 13(9): 2751-2757, 2007. (Design, data analysis, manuscript writing).

Badros A, Goloubeva O.G., Dalal JS, Can I, Thompson J, Rapoport AP, Akpek G, Ruehle Heyman M, Fenton RG. Neurotoxicity of bortezomib therapy in multiple myeloma A single-center experience and review of the literature. Cancer, 110 (5): 1042-9, 2007. (Data analysis, manuscript writing).

Walser TC, Ma X, Kundu N, Goloubeva O, Fulton AM.  Immune-mediated modulation of breast cancer growth and metastasis by the chemokine Mig(CXCL9) in a murine model. J Immunother. 30(5): 490-8, 2007. (Data analysis, manuscript writing).

Sabnis G, Macedo L, Goloubeva O, Schayowitz A, Zhu Y, Brodie A. Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model. J Steroid Biochem Mol Biol, 108 (1-2): 1-7, 2008. (Data analysis, manuscript writing).

Tang Y, Wang L, Goloubeva O, Afnan Khan M, Zhang B, Hussain A. Divergent Effects of Castration on Prostate Cancer in TRAMP Mice: Possible Implications for Therapy. Clin Cancer Res 14 (10): 2936-43, 2008. (Design, data analysis, manuscript writing).

Sabnis GJ, Macedo LF, Goloubeva O, Schayowitz A, Brodie AM. Stopping treatment can reverse acquired resistance to letrozole. Cancer Res 68 (12): 4518-24, 2008. (Data analysis, manuscript writing).

Schumaker L, Nikitakis N, Goloubeva O, Tan M, Taylor R, Cullen KJ. Elevated expression of glutathione S-transferase p and p53 confers poor prognosis in head and neck cancer patients treated with chemoradiotherapy but not radiotherapy alone. Clin Cancer Res 14 (18): 5877-83, 2008. (Data analysis, manuscript writing).

Badros A, Terpos E, Katodritou E, Goloubeva O, Kastritis E, Verrou E, Zervas K, Baer MR, Meiller T, Dimopoulos MA. Natural History of Osteonecrosis of the Jaw in Patients with Multiple Myeloma. J Clin Oncol 26 (36): 5904-5909, 2008. (Data analysis, manuscript writing).

Alexiev B, Darwin P, Goloubeva O, Ioffe O.  Proliferative rate in endoscopic ultrasound fine needl aspiration of pancreatic endocrine tumors: correlation with behaviour. Cancer (Cancer Cytopathol). 117: 40-45, 2009. (Data analysis, manuscript writing).

Tkaczuk KH, Tait NS, Ioffe O, Tan M, Goloubeva O, Lesko SA, Lum ZP, Deamond S, Van Echo DA, Ts'o PO. Drug Response Indicator Test (DRIT) - a diagnostic procedure for predicting treatment outcome of anticancer chemotherapy for metastatic breast cancer patients. Cancer (accepted), 2009. (Data analysis, manuscript writing).

Kundu N, Ma X, Holt D, Goloubeva O, Ostrand-Rosenberg S, Fulton AM. Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function. Breast Cancer Res Treat Sept 117(2): 235-42, 2009. (Data analysis, manuscript writing).

Badros A, Burger AM, Philip S, Niesvizky R, Kolla SS, Goloubeva O, Harris C, Zweibel J, Wright JJ, Espinoza-Delgado I, Baer MR, Hollerand JL, Egorin MJ, Grant S. Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma. Clin Cancer Res Aug 15: 15 (16): 5250-7, 2009. (Design, data analysis, manuscript writing).

Kevin J Cullen, Lisa Schumaker, Nikolaos Nikitakis, Olga Goloubeva,   Ming Tan, Nicholas J Sarlis, Robert I Haddad, and Marshall R Posner.  -Tubulin-II Expression Strongly Predicts Outcome in Patients Receiving Induction Chemotherapy for Locally Advanced Squamous Carcinoma of the Head and Neck. A Companion Analysis of the TAX 324 Trial. JCO 27(36): 6222-8, 2009. (Data analysis, manuscript writing).

Settle K, Posner MR, Schumaker L, Tan M, Sunthararligam M, Goloubeva O, Strome SE, Haddad RI, Patel S, Cambell E, Sarlis N, Cullen K. Racial Outcome Disparity in Head and Neck Cancer Results from Low Prevalence of HPV Infection in Black Patients with Oropharyngeal Cancer. Cancer Prevention Research 2(9): 776-81, 2009. (Data analysis, manuscript writing).

Sabnis GJ, Schayowitz A, Goloubeva O, Macedo LF, Brodie AM. Trastuzumab Reverses Letrozole Resistance and Amplifies the Sensitivity of Breast Cancer Cells to Estrogen. Cancer Res 69 (4): 1416-28, 2009. (Design, data analysis, manuscript writing).

Sabnis GJ, Goloubeva O, Gilani R., Macedo LF, Brodie AM. Sensitivity to the Aromatase Inhibitor Letrozole is Prolonged After a â?oBreakâ? in Treatment . Mol Cancer Ther 9(1): 46-56, 2010. (Data analysis, manuscript writing).

Ma X, Kundu N, Rodgers WH, Gimottty PA Goloubeva O, Lipsky M, Li Y, Fulton AM. CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol Cancer Ther 8(3): 490-8, 2010. (Data analysis, manuscript writing).

Paul B, Trovato Ja, Thompson J, Badros AZ, Goloubeva O. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoetic stem cell support. J Oncol Pharm Pract Mar; 16(1): 45-51, 2010. (Data analysis, manuscript writing).

A.Hussain, Y.Wu, A.Mirmiran, O.Goloubeva, B.Bridges, H.Mannuel, C.Engstrom, N.Dawson, P.Amin, Y.Kwok. Long-term follow-up of a prospective trial of trimodality therapy of weekly pacitazel, radiation, and indrogen deprivation in high-risk prostate cancer with or without prior prostectomy. Int.J. Radiation Oncology Biol. Phys. 2010, October  30. (Data analysis, manuscript writing).

Koshy M, Goloubeva O, Suntharalingam M. Impact of Neoadjuvant Radiation on Survival in Stage III Non-Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2010 Jun 2. (Data analysis, manuscript writing).

Gauri Sabnis, Olga Goloubeva, Saranya Chumsri, Nguyen Nguyen, Saraswati
Sukumar, and Angela Brodie. Functional reactivation of the estrogen receptor-and        aromatase by the HDAC inhibitor, entonostat, increases sensitivity of ER-negative tumors to letrozole. Cancer Res, 2011. Mar 1: 71(5): 1893-903. (Data analysis, manuscript writing).

Marshal Posner, Jochen H Lorch, Olga Goloubeva, Ming Tan, Nicholas Sarlis, Robert Haddard, Kevin Cullen. Survival and Human Papillomavirus in Oropharynx Cancer in TAX 324:  A Subset Analysis from an International Phase III Trial. Annals of Oncology. Accepted. January 2011. (Data analysis, manuscript writing).

Lorch J, Goloubeva O, Haddard R., Cullen K., Sarlis N., Tan M., Posner M: Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncology. 2011 Feb: 12(2):153-9. (Data analysis, manuscript writing).

Lorch J, Goloubeva O, Posner M: How does TPF improve survival over PF? Authorsâ?T reply. Lancet Oncology, 2011 May; 12(5): 421-2.

Suntharalingam M, Kwok Y, Goloubeva O, Parekh A, Taylor R, Wolf J, Zimrin A, Strome S, Ord R, Cullen KJ. Phase II Study Evaluating the Addition of Cetuximab to the Concurrent Delivery of Weekly Carboplatin, Paclitaxel, and Daily Radiotherapy for Patients With Locally Advanced Squamous Cell Carcinomas of the Head and Neck. Int J Radiat Oncol Biol Phys. 2011 May 19 (Data analysis, manuscript writing).

Neuner G, Mohiuddin MM, Walde NV, Goloubeva O, Yu CX, Regine WF. High-dose spatially fractionated GRID radiation therapy (SFGRT): a comparison of treatment outcomes with cerrobend vs. MLC SFGRT. Int J Radiat Oncol Biol Phys. 2011 April 29 (Data analysis, manuscript writing).

Kundu N, Campbell P, Hampton B, Lin CY, Ma X, Ambulos N, Zhao XF, Goloubeva O, Holt D, Fulton AM. Antimetastatic activity isolated from Colocasia esculenta Anticancer Drugs. 2011 Sep 22.

Tkaczuk KH, Tait NS, Ioffe O, Tan M, Goloubeva OG, Lesko SA, Deamond SF, Zhou D, Lum ZP, Sutula MJ, Van Echo D, Ts'o PO. Computer assisted quantitative immunofluorescence of tumor tissue marker expression and clinical outcome to chemotherapy in advanced breast cancer patients. Discov Med. 2011 Jul;12(62):33-40.

Ma X, Kundu N, Collin PD, Goloubeva O, Fulton AM. Frondoside A inhibits breast cancer metastasis and antagonizes prostaglandin E receptors EP4 and EP2.Breast Cancer Res Treat. 2011 Jul 15.

Usama Mahmood; Matthew Koshy; Olga Goloubeva; Mohan Suntharalingam. Adjuvant Radiation Therapy for High-Grade and/or Locally Advanced Major Salivary Gland Tumors. Arch Otolaryngol Head Neck Surg. 2011;137(10):1025-1030.